earnings
confidence high
sentiment positive
materiality 0.75
CVS Q3 GAAP loss $(2.60) on opioid/LTC charges; adj. EPS $2.09 beat; raises full-year adj. guidance
CVS HEALTH Corp
2022-Q3 EPS reported
$1.40
revenue$238,621,000,000
- Total revenues $81.2B (+10.0% YoY); GAAP diluted loss per share $(2.60) vs $1.20 EPS prior year.
- GAAP results include $5.2B pre-tax opioid litigation charge and $2.5B pre-tax loss on LTC business held for sale.
- Adjusted EPS of $2.09 vs $1.97 prior year; full-year adj. EPS guidance raised to $8.55-$8.65 from $8.40-$8.60.
- Full-year GAAP EPS guidance lowered to $3.12-$3.22 from $7.23-$7.43 due to the charges.
- Agreed to acquire Signify Health for $30.50/share (~$8B total); repaid $2.6B debt and paid $726M dividends in Q3.